Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice
A Goury, A Meghraoui-Kheddar… - The Journal of …, 2015 - journals.aai.org
The receptor for advanced glycation end products (RAGE) is a pattern recognition receptor
that interacts with advanced glycation end products, but also with C3a, CpG DNA …
that interacts with advanced glycation end products, but also with C3a, CpG DNA …
[HTML][HTML] Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and …
…, B Painvin, T Kamel, AW Thille, A Goury… - Intensive Care …, 2022 - Springer
Purpose Management and outcomes of pregnant women with coronavirus disease 2019 (COVID-19)
admitted to intensive care unit (ICU) remain to be investigated. Methods A …
admitted to intensive care unit (ICU) remain to be investigated. Methods A …
Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill coronavirus disease 2019 patients
V Dupont, L Kanagaratnam, A Goury… - Clinical Infectious …, 2021 - academic.oup.com
Excess soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble inhibitor of vascular endothelial
growth factor pathway, has been demonstrated to promote endothelial dysfunction. Here, we …
growth factor pathway, has been demonstrated to promote endothelial dysfunction. Here, we …
[HTML][HTML] Targeted temperature management using the “Esophageal Cooling Device” after cardiac arrest (the COOL study): a feasibility and safety study
A Goury, F Poirson, U Chaput, S Voicu, P Garçon… - Resuscitation, 2017 - Elsevier
Background Targeted temperature management (TTM) between 32 and 36 C is recommended
after out-of-hospital cardiac arrest (OHCA). We aimed to assess the feasibility and safety …
after out-of-hospital cardiac arrest (OHCA). We aimed to assess the feasibility and safety …
[HTML][HTML] The eight unanswered and answered questions about the use of vasopressors in septic shock
O Hamzaoui, A Goury, JL Teboul - Journal of Clinical Medicine, 2023 - mdpi.com
Septic shock is mainly characterized—in addition to hypovolemia—by vasoplegia as a
consequence of a release of inflammatory mediators. Systemic vasodilatation due to depressed …
consequence of a release of inflammatory mediators. Systemic vasodilatation due to depressed …
[HTML][HTML] Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients
A Kisserli, N Schneider, S Audonnet, T Tabary, A Goury… - Immunobiology, 2021 - Elsevier
In order to study the mechanisms of COVID-19 damage following the complement activation
phase occurring during the innate immune response to SARS-CoV-2, CR1 (the regulating …
phase occurring during the innate immune response to SARS-CoV-2, CR1 (the regulating …
Algorithm for rational use of Film Array Pneumonia Panel in bacterial coinfections of critically ill ventilated COVID-19 patients
E Novy, A Goury, C Thivilier, T Guillard… - … and Infectious Disease, 2021 - Elsevier
The FilmArray Pneumonia Panel has proven to be an effective tool for rapid detection of
main respiratory pathogens. However, its rational use needs appropriate knowledge and …
main respiratory pathogens. However, its rational use needs appropriate knowledge and …
[HTML][HTML] Predictive factors associated with high‐flow nasal cannula success for COVID‐19‐related acute hypoxemic respiratory failure
A Goury, JA Moussanang, M Bard… - Health Science …, 2021 - ncbi.nlm.nih.gov
… Dr GOURY had full access to all of the data in this study and takes complete responsibility
… Dr Goury affirms that this manuscript is an honest, accurate, and transparent account of the …
… Dr Goury affirms that this manuscript is an honest, accurate, and transparent account of the …
[HTML][HTML] Post-intensive care syndrome prevalence six months after critical COVID-19: comparison between first and second waves
… Amandine RAPIN, MD, MHP, corresponding author 1, 2 François Constant BOYER, MD,
MHP, PhD, 1, 2 Bruno MOURVILLIER, MD, PhD, 3 Guillaume GIORDANO ORSINI, MD, 3 …
MHP, PhD, 1, 2 Bruno MOURVILLIER, MD, PhD, 3 Guillaume GIORDANO ORSINI, MD, 3 …
Treatment of severe COVID-19: a role for JAK and complement inhibitors?
A Goury, B Mourvillier - The Lancet Respiratory Medicine, 2023 - thelancet.com
Comment 2 www. thelancet. com/respiratory Published online November 14, 2023 https://doi.
org/10.1016/S2213-2600 (23) 00423-X favour of JAK inhibitors, mainly baricitinib. Among …
org/10.1016/S2213-2600 (23) 00423-X favour of JAK inhibitors, mainly baricitinib. Among …
